[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Snead et al., 2014 - Google Patents

Alpha-synuclein function and dysfunction on cellular membranes

Snead et al., 2014

View HTML
Document ID
8102892052024422822
Author
Snead D
Eliezer D
Publication year
Publication venue
Experimental neurobiology

External Links

Snippet

Alpha-synuclein is a small neuronal protein that is closely associated with the etiology of Parkinson's disease. Mutations in and alterations in expression levels of alpha-synuclein cause autosomal dominant early onset heredity forms of Parkinson's disease, and sporadic …
Continue reading at www.ncbi.nlm.nih.gov (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Similar Documents

Publication Publication Date Title
Snead et al. Alpha-synuclein function and dysfunction on cellular membranes
Ghosh et al. α-synuclein aggregation and its modulation
Stroo et al. Cellular regulation of amyloid formation in aging and disease
Bridi et al. Mechanisms of α-synuclein induced synaptopathy in Parkinson's disease
Ottolini et al. Alpha-synuclein at the intracellular and the extracellular side: functional and dysfunctional implications
Choi et al. Crucial role of protein oligomerization in the pathogenesis of Alzheimer's and Parkinson's diseases
Wales et al. Limelight on alpha-synuclein: pathological and mechanistic implications in neurodegeneration
Ghiglieri et al. Alpha-synuclein: from early synaptic dysfunction to neurodegeneration
Burré et al. Cell biology and pathophysiology of α-synuclein
O’Hara et al. LRRK2 and α-synuclein: distinct or synergistic players in Parkinson’s disease?
Manzanza et al. Alpha-synuclein post-translational modifications: implications for pathogenesis of lewy body disorders
Uversky Neuropathology, biochemistry, and biophysics of α‐synuclein aggregation
Alberio et al. Cellular models to investigate biochemical pathways in Parkinson’s disease
Xu et al. The phosphorylation of α‐synuclein: development and implication for the mechanism and therapy of the Parkinson's disease
Deleersnijder et al. The remarkable conformational plasticity of alpha-synuclein: blessing or curse?
Kanaan et al. Loss of functional alpha-synuclein: a toxic event in Parkinson's disease?
Jiang et al. Membrane remodeling by α-synuclein and effects on amyloid formation
Tofaris et al. Physiological and pathological properties of α-synuclein
Beyer Mechanistic aspects of Parkinson’s disease: α-synuclein and the biomembrane
Runwal et al. The membrane interactions of synuclein: physiology and pathology
Olivares et al. Physiological and pathological role of alpha-synuclein in Parkinson’s disease through iron mediated oxidative stress; the role of a putative iron-responsive element
Sarchione et al. Alpha-synuclein and lipids: the elephant in the room?
Yang et al. LRRK2 kinase activity mediates toxic interactions between genetic mutation and oxidative stress in a Drosophila model: suppression by curcumin
Bar‐On et al. Effects of the cholesterol‐lowering compound methyl‐β‐cyclodextrin in models of α‐synucleinopathy
Lee et al. Genetic factors involved in the pathogenesis of Parkinson's disease